Clover Health Investments, Corp. (NASDAQ:CLOV – Get Free Report) CEO Conrad Wai sold 300,000 shares of Clover Health Investments stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $4.72, for a total transaction of $1,416,000.00. Following the completion of the transaction, the chief executive officer owned 1,170,056 shares of the company’s stock, valued at $5,522,664.32. This trade represents a 20.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Clover Health Investments Stock Down 1.8%
Clover Health Investments stock opened at $4.46 on Friday. Clover Health Investments, Corp. has a 52-week low of $1.58 and a 52-week high of $5.59. The firm has a market cap of $2.37 billion, a PE ratio of -89.18 and a beta of 2.47. The company’s 50 day moving average is $4.42 and its two-hundred day moving average is $3.63.
Clover Health Investments (NASDAQ:CLOV – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. The business had revenue of $743.17 million for the quarter, compared to analyst estimates of $728.27 million. Clover Health Investments had a negative return on equity of 4.20% and a negative net margin of 0.74%. On average, equities research analysts anticipate that Clover Health Investments, Corp. will post 0.06 earnings per share for the current fiscal year.
Institutional Trading of Clover Health Investments
Analyst Ratings Changes
A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft initiated coverage on Clover Health Investments in a research report on Thursday, September 10th. They issued a “buy” rating and a $6.00 price target on the stock. Canaccord Genuity Group upped their target price on shares of Clover Health Investments from $4.20 to $5.50 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clover Health Investments in a report on Wednesday, June 24th. Wall Street Zen downgraded shares of Clover Health Investments from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 16th. Finally, Zacks Research upgraded shares of Clover Health Investments to a “hold” rating in a report on Monday, September 14th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.75.
Read Our Latest Research Report on Clover Health Investments
Clover Health Investments Company Profile
Clover Health Investments, Inc is a healthcare technology and insurance company focused on providing Medicare Advantage plans to eligible Medicare beneficiaries. Its insurance business offers medical coverage and related healthcare benefits through plans available in select counties across the United States.
The company also develops and uses Clover Assistant, a technology platform designed to support physicians with patient information, clinical insights, care recommendations and tools intended to help improve healthcare outcomes.
Further Reading
- Five stocks we like better than Clover Health Investments
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.
